AACR Round-Up: BMS, Lilly, iTeos, Affimed, Treovir, Revolution And Cardiff

Immuno-Oncology Highlights Include TIGIT, NK Cell Booster & HSV Oncolytic

iTeos presents early anti-TIGIT results, Affimed reports 100% response rate in Hodgkin lymphoma, Treovir will start a pivotal Phase II after Phase I pediatric glioma study, updates in KRAS-mutated cancers from Revolution Medicines and Cardiff Oncology, plus Opdivo plus chemo shows complete responses in neoadjuvant lung cancer and Lilly’s Retevmo is active in additional tumors.

Cancer cell 3D
Immunotherapy boosters, an oncolytic HSV therapy and other novel therapies were presented at AACR • Source: Shutterstock

Elaborating on top-line data it announced last October, Bristol Myers Squibb Company reported on 10 April that Opdivo can yield pathologic complete response in pre-surgical non-small cell lung cancer patients, the first time an immunotherapy has demonstrated pathological response in a Phase III study in neoadjuvant lung cancer.

The pharma outlined the early data from its CheckMate-816 trial in October saying Opdivo (nivolumab) plus chemotherapy bested chemotherapy alone...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D